
BCAX Stock Forecast & Price Target
BCAX Analyst Ratings
Bulls say
Bicara Therapeutics' stock outlook appears positive due to the superior efficacy of its ficerafusp alfa therapy, which demonstrates a meaningful enhancement over existing treatments, specifically achieving an objective response rate (ORR) that exceeds those of Keytruda and its combination therapies. The clinical data reveals a median progression-free survival (mPFS) of 9.9 months and a median overall survival (mOS) of 21.3 months when ficerafusp alfa is combined with Keytruda, suggesting significant improvements in patient outcomes compared to existing therapies, which report lower mOS rates. These promising clinical results position Bicara Therapeutics favorably in the competitive landscape of biopharmaceuticals, particularly for patients with solid tumors.
Bears say
Bicara Therapeutics Inc reported a net loss of $0.50 per share for the second quarter of 2025, consistent with prior estimates, indicating ongoing financial challenges. The company faces significant risks, including potential negative clinical results for its lead drug ficerafusp alfa, delays in trial advancements, and difficulties in obtaining timely regulatory approvals, which could hinder future growth. Additionally, long-term dilution risk and competitive pressures from other bispecific therapies in development further contribute to a negative financial outlook for the company.
This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BCAX Analyst Forecast & Price Prediction
Start investing in BCAX
Order type
Buy in
Order amount
Est. shares
0 shares